Home Press Release Former FDA Adviser, World Renowned Medical Expert, And Member Of The Team That Created HIPAA To Join Ehave Advisory Board Published: May 27, 2020 at 10:12 a.m. ET 0 Email icon Facebook icon Twitter icon Linkedin icon Flipboard icon Print icon Resize icon The MarketWatch News Department was not involved in the creation of this content. May 27, 2020 (ACCESSWIRE via COMTEX) -- Victor S. Dorodny, MD, PhD, MPH to advise Ehave utilizing his 45+ years of medical experience and 15+ years of telemedicine experience. MIAMI, FL / ACCESSWIRE / May 27, 2020 / Ehave, Inc., (OTC PINK:EHVVF) (the "Company"), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today the Company plans to utilize Telemedicine as part of its platform. Victor S. Dorodny, MD, PhD, MPH will advise Ehave on HIPAA compliance, as well as its proprietary telemedicine technology. Advertisement Dr. Dorodny was one of the creators of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). He has served on the Advisory Board of the Association of Medical Director of Information Systems and is the Past President of the Western Division of the National Association of Managed Care Physicians. Dr. Dorodny has served in an executive capacity of several companies where he has held the title of Chief Medical Information Officer, Chief Scientific Advisor, and Chief Medical Officer. As a world renowned speaker, he has spoken at hearings in front of Congress, the California Senate Judiciary Committee, and the FDA-Pharmaceutical Services and Information Exchange. Over the course of his esteemed 45 year medical career, Dr. Dorodny has also been a speaker at dozens of medical conferences. In addition to his impressive medical background, Dr. Dorodny was a pioneer in the telemedicine industry, serving as CMO & Global Practice Leader for US Telemedicine from 2006 to 2009. He received his advanced medical degrees from the University of Odessa Medical School, Albert Einstein College of Medicine, and the University of Southern California. In his role advising Ehave on HIPAA compliance, Dr. Dorodny will address specific areas of concern with Ehave's Board of Directors to ensure privacy policies are enforced. Additionally, he will oversee ongoing employee privacy training, conduct risk assessments, and develop HIPAA-compliant procedures where necessary. Dr. Dorodny will also advise Ehave on the effective implementation of its proprietary telemedicine technology. According to a May 29, 2019 article by the American Medical Association, "A national study of insurance claims filed for alternative settings of care found telehealth rocketed up 53% from 2016 to 2017. That growth greatly outpaced other places studied-14% at urgent care centers, 7% at retail clinics, and 6% at ambulatory surgical centers (ASCs)." [1] "For a small company, engaging a medical professional with the qualifications of Dr. Dorodny to oversee our HIPAA compliance, as well as its proprietary telemedicine technology, is a major step in completing our business plan," said Ben Kaplan, CEO of Ehave. "We look forward to sharing more about our upcoming proprietary telemedicine technology with our shareholders. We have made a commitment to Psychedelic Medicine with our recent PsyTech acquisition and welcome Dr. Dorodny to our team." NOW PLAYING: Hong Kong Protests Reignite Over Beijing Security Laws Visit our Video Center About Ehave, Inc. Ehave, Inc. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, psychedelics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes meeting privacy and HIPAA & GDPR Compliant. Our main product is the Ehave Dashboard which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insight using Blockchain technology. The Ehave dashboard offers Offline Encrypted Digital Records Empowering Healthcare providers and patients and it's a powerful machine learning and artificial intelligence platform using artificial intelligence to extract deep insights from audio, video and text to improve research with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.

Press Release

Former FDA Adviser, World Renowned Medical Expert, And Member Of The Team That Created HIPAA To Join Ehave Advisory Board

Published: May 27, 2020 at 10:12 a.m. ET

0

• Email icon
• Facebook icon
• Twitter icon
• Linkedin icon
• Flipboard icon

• Print icon
• Resize icon

The MarketWatch News Department was not involved in the creation of this content.

May 27, 2020 (ACCESSWIRE via COMTEX) -- Victor S. Dorodny, MD, PhD, MPH to advise Ehave utilizing his 45+ years of medical experience and 15+ years of telemedicine experience.

MIAMI, FL / ACCESSWIRE / May 27, 2020 / Ehave, Inc., (OTC PINK:EHVVF) (the "Company"), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today the Company plans to utilize Telemedicine as part of its platform. Victor S. Dorodny, MD, PhD, MPH will advise Ehave on HIPAA compliance, as well as its proprietary telemedicine technology.

Advertisement

Dr. Dorodny was one of the creators of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). He has served on the Advisory Board of the Association of Medical Director of Information Systems and is the Past President of the Western Division of the National Association of Managed Care Physicians. Dr. Dorodny has served in an executive capacity of several companies where he has held the title of Chief Medical Information Officer, Chief Scientific Advisor, and Chief Medical Officer. As a world renowned speaker, he has spoken at hearings in front of Congress, the California Senate Judiciary Committee, and the FDA-Pharmaceutical Services and Information Exchange. Over the course of his esteemed 45 year medical career, Dr. Dorodny has also been a speaker at dozens of medical conferences. In addition to his impressive medical background, Dr. Dorodny was a pioneer in the telemedicine industry, serving as CMO & Global Practice Leader for US Telemedicine from 2006 to 2009. He received his advanced medical degrees from the University of Odessa Medical School, Albert Einstein College of Medicine, and the University of Southern California.

In his role advising Ehave on HIPAA compliance, Dr. Dorodny will address specific areas of concern with Ehave's Board of Directors to ensure privacy policies are enforced. Additionally, he will oversee ongoing employee privacy training, conduct risk assessments, and develop HIPAA-compliant procedures where necessary. Dr. Dorodny will also advise Ehave on the effective implementation of its proprietary telemedicine technology. According to a May 29, 2019 article by the American Medical Association, "A national study of insurance claims filed for alternative settings of care found telehealth rocketed up 53% from 2016 to 2017. That growth greatly outpaced other places studied-14% at urgent care centers, 7% at retail clinics, and 6% at ambulatory surgical centers (ASCs)." [1]

"For a small company, engaging a medical professional with the qualifications of Dr. Dorodny to oversee our HIPAA compliance, as well as its proprietary telemedicine technology, is a major step in completing our business plan," said Ben Kaplan, CEO of Ehave. "We look forward to sharing more about our upcoming proprietary telemedicine technology with our shareholders. We have made a commitment to Psychedelic Medicine with our recent PsyTech acquisition and welcome Dr. Dorodny to our team."

NOW PLAYING: Hong Kong Protests Reignite Over Beijing Security Laws

Visit our Video Center

About Ehave, Inc.

Ehave, Inc. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, psychedelics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes meeting privacy and HIPAA & GDPR Compliant. Our main product is the Ehave Dashboard which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insight using Blockchain technology. The Ehave dashboard offers Offline Encrypted Digital Records Empowering Healthcare providers and patients and it's a powerful machine learning and artificial intelligence platform using artificial intelligence to extract deep insights from audio, video and text to improve research with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.

And you thought it's almost over@?

• Sign in
• Join now

More health risks as offices reopen

Updated 6 hours ago

The coronavirus won't be the only health threat lurking in office buildings once they reopen. Stanlgnant water in dormant plumbing may carry Legionnaire's disease, which kills 1 out of every 10 people. Health officials say the bacteria spreads quickly when toilets are flushed and bathroom taps are turned on. Research also shows that rlevators are breeding grounds for illnesses, since droplets can linger in hard-to-ventilate spaces long after someone exits. Meantime, labor watchdog OSHA has issued ipdated guidelines beefing up in-person workplace inspections and prioritizing those involving the coronavirus.

On the frontlines!

Amazing DrD on the front lines of fighting off

the enemy of the humanity!

COVID-19

MAY 12, 2020

Smoking and COPD associated with higher COVID-19 mortality

By Denise Baez

Current smokers and people with chronic obstructive pulmonary disease (COPD) who contract coronavirus disease 2019 (COVID-19) have an increased risk of severe complications and higher mortality with COVID-19 infection, according to a study published in PLOS ONE.

Jaber Alqahtani, University College London, London, United Kingdom, and colleagues scrutinised data from 15 studies comprising 2,473 patients with laboratory-confirmed COVID-19. Data were extracted by 2 independent authors in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.

The crude case fatality rate of COVID-19 was 7.4%. The pooled prevalence rate of patients with COPD with COVID-19 was 2% and 9% for smokers with COVID-19. Patients with COPD were at a higher risk of more severe disease (risk of severity = 63%) compared with patients without COPD (33.4%), and had a higher mortality risk (60% vs 55%).

Of current smokers, 22% had severe complications compared with 46% of ex-smokers. In addition, current smokers were 1.45 times more likely to have severe complications compared with former and never smokers. Current smokers also had a higher mortality rate of 38.5%.

“To the best of our knowledge, this is the first systematic review and meta-analysis to develop an informed understanding of the prevalence, severity and mortality of patients with COPD diagnosed with COVID-19,” the authors wrote.

“Although COPD prevalence in COVID-19 cases was low in current reports, COVID-19 infection was associated with substantial severity and mortality rates in COPD,” they added. “Compared with former and never smokers, current smokers were at greater risk of severe complications and higher mortality rate. Effective preventive measures are required to reduce COVID-19 risk in patients with COPD and current smokers.”

“Having a reliable estimate of the prevalence of COPD in COVID-19 cases, and likely outcomes, is crucial to ensure specific successful global preventive and treatment strategies for patients with COPD,” the authors added. “Bearing this in mind, in the included studies there was no report on COPD severity data and COPD-related comorbidities, which prevents us from assessing the impact of such essential information.”

Reference: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0233147

SOURCE: PLOS One

Remdesivir accelerates COVID-19 recovery in US randomised trial, results from another remdesivir trial from China

By Denise Baez

NEW YORK -- April 30, 2020 -- In this DG Alert, we look at results from the first 2 randomised controlled trials (RCTs) of remdesivir for coronavirus disease 2019 (COVID-19).

Preliminary data from the first RCT evaluating remdesivir for hospitalised patients with severe COVID-19 and lung involvement in the United States showed that those who received remdesivir recovered faster than placebo-treated patients. 

The Adaptive COVID-19 Treatment Trial (ACTT) began on February 21, 2020, and is sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

An independent data and safety monitoring board (DSMB) overseeing the trial met on April 27, 2020, to review data from 1,063 patients and share their interim analysis with the study team. Based upon their review of the data, they noted that remdesivir was better than placebo from the perspective of the primary endpoint, which is time to recovery -- defined as being well enough for hospital discharge or returning to normal activity level.

Preliminary results indicate that patients who received remdesivir had a 31% faster time to recovery than those who received placebo (P< 0.001). Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo.

Results also suggested a survival benefit, with a mortality rate of 8.0% in the remdesivir group compared with 11.6% in the placebo group (P = 0.059).

More detailed information about the trial results, including more comprehensive data, will be available in a forthcoming report.

Findings from another, but smaller RCT of remdesivir, published in The Lancet, arrived at different conclusions. 

The study, which involved 237 critically ill adults with COVID-19 from 10 hospitals in Wuhan, China, showed that treatment with remdesivir did not speed-up recovery compared with placebo. 

However, the authors cautioned that interpretation of their findings is limited because the study was stopped early by the DSMB because of difficulty recruiting patients after the outbreak in Wuhan was brought under control.

“Unfortunately, our trial found that while safe and adequately tolerated, remdesivir did not provide significant benefits over placebo”, said Bin Cao, MD, China-Japan Friendship Hospital, Beijing, China. “This is not the outcome we hoped for, but we are mindful that we were only able to enrol 237 of the target 453 patients because the COVID-19 outbreak was brought under control in Wuhan. What’s more, restrictions on bed availability resulted in most patients being enrolled later in the disease course, so we were unable to adequately assess whether earlier treatment with remdesivir might have provided clinical benefit.”

Between February 6, 2020, and March 12, 2020, the researchers enrolled 237 adults hospitalised with severe laboratory-confirmed severe COVID-19. To be eligible, patients had to enter the study within 12 days of symptom onset, have pneumonia confirmed by chest imaging, and oxygen saturation of ≤94%. Participants were randomised to daily infusions of remdesivir (n = 158; 200 mg on day 1 followed by 100 mg on days 2 to 10) or placebo infusions (n = 79) for 10 days. One patient in the placebo group withdrew before receiving treatment. Patients were permitted concomitant use of lopinavir/ritonavir, interferons, and corticosteroids.

The primary endpoint was time to clinical improvement up to day 28, defined as the time (in days) from randomisation to the point of a decline of 2 levels on a 6-point ordinal scale of clinical status (from 1 = discharged to 6 = death) or discharged alive from hospital, whichever came first. Primary analysis was done in the intention-to-treat (ITT) population and safety analysis was done in all patients who started their assigned treatment.

Use of remdesivir was not associated with a difference in time to clinical improvement. Average time to clinical improvement was 21 days for the remdesivir group versus 23 days for the placebo group (hazard ratio [HR] = 1.23; 95% confidence interval [CI], 0.87-1.75). 

Although not statistically significant, patients receiving remdesivir had a numerically faster time to clinical improvement than those receiving placebo among patients with symptom duration of ≤10 days (mean 18 days vs 23 days; HR = 1.52; 95% CI, 0.95-2.43). 

Death within 28 days of randomisation was similar between the remdesivir and placebo groups (14% vs 13). However, patients treated with remdesivir within 10 days of illness onset had a lower mortality rate (11% vs 15%), although the difference was not statistically significant. 

Duration of invasive mechanical ventilation was a mean 7 days in the remdesivir group compared with a mean 15.5 days in the placebo group, but the difference was not statistically significant.

Treatment with remdesivir did not result in significant reductions in viral load or detection of the virus in the upper or lower respiratory tract compared with placebo.

“Participants in our trial were less ill, and treated earlier in their disease course, compared with a recent observational study of patients with COVID-19, who received remdesivir on compassionate grounds,” said Ronghui Du, MD, Wuhan Lung Hospital. “Yet, remdesivir did not provide greater benefits in our study population as expected. Ongoing clinical trials of remdesivir will provide important additional information about whether and under what circumstances it may provide benefit.”

The authors noted several limitations to their study, including that stopping early gives insufficient power to detect differences in clinical outcomes, and it did not account for the possible emergence of reduced susceptibility to remdesivir because of a lack of data at the time. They pointed out that the frequent use of corticosteroids in patients in the study might have aided viral production. 

Reference: https://www.nih.gov/news-events/news-releases/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19

SOURCE: National Institutes of Health, The Lancet

COVID-19

APRIL 29, 2020

Pregnant women with COVID-19 have comparable clinical outcomes with reproductive-aged non-pregnant women

Pregnant women have comparable clinical course and outcomes compared with reproductive-aged non-pregnant women when infected with SARS-CoV-2, according to a study published in the International Journal of Infectious Diseases. 

The study also concluded that no evidence supported vertical transmission of COVID-19 in the late stage of pregnancy including vaginal delivery.

Xu Qiancheng, The Central Hospital of Wuhan, Wuhan, China, and colleagues retrospectively reviewed medical records of pregnant and reproductive-aged non-pregnant women hospitalized with COVID-19 from January 15 to March 15, 2020. The severity of disease, virus clearance time, and length of hospital stay were measured as the primary interest and the vertical transmission potential of COVID-19 was also assessed.

The study enrolled 82 patients (28 pregnant women, 54 reproductive-aged non-pregnant women) with laboratory confirmed COVID-19. The median age of pregnant women was 30 (interquartile range [IQR] = 26.75-32) years that was similar to that of non-pregnant women of 31 (IQR = 28-35) years. The median gestational age of the pregnant women on admission was 38 (IQR = 36.5-39) weeks. Comorbidities were not frequently reported in both groups.

According to study data, the severity of disease was comparable in the two groups. Apart from 2 (7.1%) patients in pregnant women presented as mild type, most patients were categorized as moderate pneumonia (24 in pregnant women (85.7%) vs. 53 in non-pregnant women (98.1%)) and only 2 (7.1%) patients in pregnant women and 1 (1.9%) in non-pregnant women were classified as severe pneumonia. 

Univariate regression indicated no association between pregnancy and the severity of disease (odds ratio [OR] = 0.73; 95% confidence interval [CI], 0.08-5.15; p = 0.76), virus clearance time (hazard ratio [HR] 1.16; 95% CI, 0.65-2.01; p = 0.62), and length of hospital stay (HR 1.10, 95% CI 0.66-1.84; p = 0.71). 

Of those pregnant women, 3 (10.7%) were in the first trimester, 1 (3.6%) in the second trimester and 24 (85.7%) in the third trimester. All pregnant women in the first and second trimester terminated pregnancy due to concerns of radiological examination and COVID-19. Two pregnant women in early third trimester continued pregnancy (30, and 33 gestational weeks, respectively). There were 22 pregnant women who delivered 23 live births either by cesarean section (17, 60.7%) or vaginal delivery (5, 17.9%) and no neonate was infected with SARS-CoV-2. The authors noted that the potential of vertical transmission is still uncertain due to the limited data and further study is warranted.

The authors noted several limitations including the majority of the patients included were presented as mild to moderate, which limited the interpretation of the results, and that more severe patients might be admitted to other hospitals, other than the study hospital.

The authors also added that all the pregnant women who delivered were infected with SARS-CoV-2 in the late stage of pregnancy, and the probability of vertical transmission during the early trimesters could not be assessed. 

Reference: https://www.ijidonline.com/article/S1201-9712(20)30280-0/fulltext

SOURCE: International Journal of Infectious Diseases